Clinical trials: Neoplasm, Oral
Head and Neck Cancer
Biomarkers in Predicting Response to Treatment in Patients With Newly Diagnosed Stage III or Stage IV Head and Neck Cancer Treated With Carboplatin, Paclitaxel, and Radiation Therapy
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00898430
- Testing
- DNA Microarray analysis, MALDI-TOF mass spectrometry, DNA microarray and MALDI-TOF mass spectrometry
- Where
- 3 sites in United States
- Volunteers
- 49 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Head and Neck Squamous Cell Carcinoma, Cancer
Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer
The purpose of this study is to compare any good or bad effects of using pembrolizumab (an experimental drug) and radiation therapy (RT), compared to using cisplatin chemotherapy and radiation therapy (RT) in the treatment of…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Cancer, Cancer of Head and Neck, Cancer, Advanced
- Trial name
- NCT03383094
- Testing
- Pembrolizumab, Radiation therapy, Cisplatin
- Where
- 6 sites in United States
- Volunteers
- 126 people
- Sponsor
- Loren Mell, MD
Head and Neck Cancer, Oral Cavity Cancer
Immune Biomarker Study for Head and Neck Cancer
The aim of this prospective non-interventional multi-center trial is to study the prognostic value of intratumoral and systemic immune biomarkers in newly diagnosed non-metastatic head and neck cancer.
- Conditions
- Head and Neck Cancer, Oral Cavity Cancer, Oropharyngeal Cancer, Hypopharyngeal Cancer
- Trial name
- ImmunBio-KHT (NCT05375266)
- Testing
- Sampling
- Where
- 3 sites in Germany
- Volunteers
- 1,100 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Neoplasms
Dose Escalation Study of Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumors
Evaluation of maximum Tolerated Dose (MTD), safety, pharmacokinetics, efficacy of BIBW 2992, pharmacodynamic modulation of biomarkers, correlation of Epidermal Growth Factor Receptor (EGFR) and Human EGF-like Receptor number 2…
- Trial name
- NCT02171637
- Testing
- BIBW 2992
- Volunteers
- 38 people
- Sponsor
- Boehringer Ingelheim
Solid Tumors, Breast Cancer
A Phase I/II Study of BGT226 in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer
This is a phase I/II clinical research study with BGT226, an inhibitor of phosphatidylinositol 3'-kinase (PI3K). The study consists of a Phase I dose escalation part followed by a safety expansion part and a Phase II expansion…
- Conditions
- Solid Tumors, Breast Cancer, Cowden Syndrome
- Trial name
- NCT00600275
- Testing
- BGT226
- Where
- 6 sites in United States, Canada and 1 more
- Volunteers
- 57 people
- Sponsor
- Novartis Pharmaceuticals
Lung Cancer, Non-small Cell Lung Cancer
Rational EpigenetiC Immunotherapy for SEcond Line Therapy in Patients With NSCLC: PRECISE Trial
The purpose of this study is to assess whether treatment with the study drug tetrahydrouridine-decitabine (THU-Dec) in combination with nivolumab is more effective than treatment with nivolumab alone in patients with NSCLC.
- Trial name
- PRECISE (NCT02664181)
- Testing
- Nivolumab, oral decitabine, Tetrahydrouridine
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Case Comprehensive Cancer Center
Head Cancer, Neck Cancer
Neurosensorial Disorder and Pain in Oral Cavity and Oropharynx Cancer Traited Patients (OCAPA)
Following preliminary studies carried out in our department on these subject and subjective findings during clinical examinations, it has been shown that pain is a symptom that is rarely reported following treatment.
- Conditions
- Head Cancer, Neck Cancer, Chronic Pain
- Trial name
- OCAPA (NCT04673981)
- Testing
- diagnostic tes for neuropathic pain
- Where
- France
- Volunteers
- 120 people
- Sponsor
- University Hospital, Clermont-Ferrand
Advanced Solid Tumor, BRAF V600 Mutation
Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors
This is a Phase I, First-In-Human, open label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-cancer activity of ABM-1310 in adult patients with locally…
- Trial name
- NCT04190628
- Testing
- ABM-1310, Cobimetinib
- Where
- 8 sites in United States
- Volunteers
- 53 people
- Sponsor
- ABM Therapeutics Corporation
Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer
Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and Neck
This phase I/II trial is studying the side effects of erlotinib and to see how well it works in treating patients with metastatic or unresectable non-small cell lung cancer, ovarian cancer, or squamous cell carcinoma (cancer) of…
- Conditions
- Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx
- Trial name
- NCT00063895
- Testing
- erlotinib hydrochloride, pharmacological study, pharmacogenomic studies
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- National Cancer Institute (NCI)
Locally Advanced Gastric Adenocarcinoma
Effect of High Protein ONS on Older Gastric Cancer Patients Receiving Neoadjuvant Chemotherapy
This interventional prospective randomized controlled study was conducted to compare the effects of high-protein oral nutritional supplement (ONS) and medical nutritional therapy to medical nutrition therapy alone on nutritional…
- Trial name
- NCT06645912
- Testing
- oral nutritional supplement
- Where
- Turkey (Türkiye)
- Volunteers
- 46 people
- Sponsor
- Erzincan Binali Yildirim University Mengucek Gazi Training and Research Hospital
Oral Cancer Directed Therapy, Breast Cancer
EHR-embedded OCDT in Breast or GI Cancer
This is research study is for participants with advanced breast or gastrointestinal cancer who have been taking oral chemotherapy medication (Oral Cancer Directed Therapy).
- Conditions
- Oral Cancer Directed Therapy, Breast Cancer, Gastrointestinal Cancer, Oral Chemotherapy
- Trial name
- NCT03858712
- Testing
- Active Care Team Alert, Passive Care Team Alert
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Dana-Farber Cancer Institute
Salivary Gland Cancer
Iressa Study in Patients With Salivary Gland Cancer
The goal of this clinical research study is to learn if ZD1839 (Iressa®, gefitinib can help to shrink or slow the growth of advanced, recurrent, or metastatic salivary gland cancer. The safety of this drug will also be studied.
- Trial name
- NCT00509002
- Testing
- Gefitinib
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- M.D. Anderson Cancer Center
Non Small Cell Lung Cancer
A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer
Lung cancer tumors become resistant to the first generation epidermal growth factor receptor (EGFR) inhibitors erlotinib or gefitinib by changing and increasing the activity of two cell signaling pathways: the cMET pathway and…
- Trial name
- NCT01121575
- Testing
- PF-02341066, PF-00299804
- Where
- 10 sites in United States, Australia
- Volunteers
- 70 people
- Sponsor
- Pfizer
Multiple Myeloma
Ixazomib, Cyclophosphamide and Dexamethasone for Multiple Myeloma
The goal of this proposal is to develop a more effective and better tolerated regimen. Ixazomib appears to have greater activity than bortezomib with less peripheral neuropathy.
- Trial name
- NCT02412228
- Testing
- Ixazomib, Cyclophosphamide, Dexamethasone
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- John L. Reagan
HNSCC, SCC - Squamous Cell Carcinoma
Window Trial of Intratumoral (IT) Neoadjuvant Fluorescently Labelled Nivolumab (nivo800) in Head and Neck Squamous Cell Carcinoma (HNSCC)
The goal of this clinical trial is to learn whether intratumoral (injected directly into the tumor) fluorescently labeled nivolumab (nivo800) is safe for adults with head and neck squamous cell carcinoma (HNSCC) who are scheduled…
- Conditions
- HNSCC, SCC - Squamous Cell Carcinoma, Oral Cancer
- Trial name
- NCT07741565
- Testing
- Nivolumab-IRDye800
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Oral Squamous Cell Carcinoma
Salivary LINC00657 as a Diagnostic Biomarker for Oral Squamous Cell Carcinoma
This study was designed to verify the role of salivary LINC00657 as a diagnostic marker in oral squamous cell carcinoma (OSCC) patients as compared to oral lichen planus (OLP) (as an example of oral potentially malignant lesions)…
- Trial name
- NCT05821179
- Where
- Egypt
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Fayoum University
Head and Neck Cancer, Acute Pain
Perioperative Gabapentin Use In Head And Neck Mucosal Surgery Patients
Patient satisfaction with healthcare is increasingly being utilized as a metric to reflect provider and hospital quality of care.
- Conditions
- Head and Neck Cancer, Acute Pain, Postoperative Pain
- Trial name
- GABA (NCT02926573)
- Testing
- Gabapentin
- Where
- United States
- Volunteers
- 123 people
- Sponsor
- Washington University School of Medicine
Brain and Central Nervous System Tumors
AEE788 and Everolimus in Treating Patients With Recurrent or Relapsed Glioblastoma Multiforme
RATIONALE: AEE788 and everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving AEE788 together with everolimus may kill more tumor cells.
- Trial name
- NCT00107237
- Testing
- AEE788, everolimus
- Where
- 3 sites in United States
- Volunteers
- 16 people
- Sponsor
- Novartis Pharmaceuticals
Head and Neck Cancer
Title XELOX FOR SALIVARY GLAND CANCERS
The goal of this clinical research study is to find out how effective oxaliplatin and capecitabine are against advanced cancer of the salivary gland.
- Trial name
- NCT00101075
- Testing
- Capecitabine, Oxaliplatin
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Dana-Farber Cancer Institute
Breakthrough Pain
Evaluate the Efficacy and Safety of ACTIQ in Patients With Cancer and Breakthrough Pain
The primary objective of the study is to determine whether a test titration regimen of ACTIQ treatment will reduce the number of inadequately managed episodes of breakthrough pain for an individual patient by attaining a…
- Trial name
- NCT00236145
- Testing
- ACTIQ (Oral transmucosal fentanyl citrate)
- Sponsor
- Cephalon